Related Experiment Videos
Suppression of delayed type hypersensitivity by desferoxamine
D M Sahasrabudhe1, J Dusel, S Jedlika
1Cancer Center, University of Rochester School of Medicine and Dentistry, New York.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy
|April 1, 1991
Summary
Desferoxamine, a chelating agent, was found to suppress T-cell immune responses in mice. This immunosuppressive effect was temporary, suggesting potential therapeutic applications.
Area of Science:
- Immunology
- Pharmacology
Background:
- Desferoxamine is a chelating agent known to inhibit T cell proliferation in vitro.
- T-cell-mediated immune responses play a crucial role in various physiological and pathological processes.
Purpose of the Study:
- To investigate the in vivo immunosuppressive effects of desferoxamine on T-cell-mediated immunity.
- To evaluate the efficacy of desferoxamine in a mouse model of delayed type hypersensitivity.
Main Methods:
- Balb/c mice were used to assess the effect of desferoxamine on the delayed type hypersensitivity reaction.
- The study evaluated desferoxamine's impact on both sensitization and elicitation phases of the skin test reactivity.
Main Results:
- Desferoxamine demonstrated significant inhibition of delayed type hypersensitivity.
- Both sensitization and elicitation of skin test reactivity were suppressed by desferoxamine.
- The observed immunosuppressive effect of desferoxamine was transient.
Conclusions:
- Desferoxamine exhibits immunosuppressive properties in vivo, specifically targeting T-cell-mediated responses.
- The transient nature of its immunosuppression suggests a potential therapeutic window.
- Further research is warranted to elucidate the precise mechanism of action and confirm its utility as an immunosuppressive agent.